Robert Frist
Analyst · Canaccord Genuity
Thank you, Mollie. Good morning, everyone and welcome to our second quarter 2021 earnings call. A lot to cover there, but I think first contact is important and I want to remind everybody that as the nation moves forward through the pandemic, it's clear that this long journey has grown bumpier in the recent rise of the Delta variant which is causing the 36% increase in the number of hospitalizations. According to the CDC, nearly half of adults in the US have been fully vaccinated and as that number rises we at HealthStream remain hopeful that progress towards beating the pandemic will continue, but we must keep in mind that as our customers are customers are one on the front lines responding to this new spike in the cases. We started today's call, I can tell you that our commitment to helping them improve the quality of healthcare has never been stronger. We were trying to align our interest in energies with our hospital customers and our continuing customers. I'll comment on branch performance for the quarter and the first half of the year. We remain laser focused on growing the company, which is why we were able to deliver another strong quarter with topline revenues increasing 7% and adjusted EBITDA increasing 20% over the same period last year to a record $14.5 million and based on those results, we have updated our financial guidance. We wanted to hit that early in the conference call. We now expect revenue for the full-year 2021 to be in the range of $253 million to $257 million. For context the midpoint of the new range is $5 million higher than the midpoint of the previous range. I believe one of the most remarkable things about this guidance is that we are projecting revenue growth despite a $38.4 million decline in revenue associated with our legacy resuscitation products from 2020 to 2021 and a $4 million to $4.3 million negative impact of acquisition related deferred revenue write-downs. So our teams have done a great job both organically and through acquisitions of backfilling those -- the revenue challenges I just articulated. Additionally, we now expect adjusted EBITDA for the full-year 2021 to increase to be in the range of $48 million to $50 million and that's compared to the range of $40 million to $44 million as announced just last quarter. There were some unique factors however that helped to contribute to the record-setting adjusted EBITDA in the first half of the year, which are not expected to repeat during the second half of the year. For example, in the first half of the year, there wasn’t much travel at all and we do expect to have projected return to travel spend. It was not at the full level of pre-pandemic, but we do expect to see travel begin to recover for HealthStreamers across the country and so we'll begin to see travel expenses come into the modeling as returned in the second half of the year. Additionally, macro workforce trends have made recruiting retention and hiring much more complex [ph] those are more difficult in the last say six months as the macro trends support everybody peeking out from the pandemic and looking around to see if there's an opportunity and no exception how should we both then, it's been a detriment and a benefit to HealthStream this trend of everybody looking for something new. So catch up on our planned hiring, we were definitely behind our plan in hiring in the first half of the year which resulted in improved EBITDA, but we need to reserve the right to catch up on our need to get the people in place that we had planned to have in place in the second half of the year and so we're doing everything we can and our new VP of HR and our recruiting teams are doing a great job adding new people, but our turnover has increased. So second half of the year we expect additional costs in personnel that were unable to net add in the first half of the year. We did have net add, but just not where we plan to be and finally we're committed to increase our investment in our newly acquired scheduling business making it into one business or one focus area in the second half of 2021 and we'll talk a bit about that here at the end of the conference call, but our new guidance reflects all three of these things for example and captures them and that guidance ranges are provided above. So I'll take a moment to comment on our financial goals for 2022 because in the last earnings call for the first time we looked for beyond 2021. As you know we had expected 2021 to be one of our toughest years with a $38 million decline in one of our product lines, but as you can tell, we found a way through that in the first half and so we wanted to get some view into 2022 where we started goals for 2022 and so here's what I can say about those now. Building on anticipate results now for 2021 our goals for 2022 are first to deliver organic high single-digit revenue growth rates and for us that's probably 7% to 9%; second, to achieve approximately 65% gross margin profile, which is fantastic because we have been delivering on that in the last two quarters at 65% gross margin profile, which was the point of several of our traditional business work we've been we've doing in the last three years that we've been talking about and so essentially we feel we've achieved that general approximate level of gross margin profile is a meaningful improvement from our historical gross margin profile and we expect to be able to continue deliver that 55% approximately into 2022. And third, we want to deliver adjusted EBITDA margins of 17% to 21% which is an increase of our previously stated goal of 15% to 20%. So a little bump in our expected taking off the bottom of the range essentially and bumping it up a little bit on our expected EBITDA margins into 2022 of the 17% to 21% and that would be an improvement of our historical norms which hover in the 17% to 18%. So we hope to be able to at least maintain historical, but hopefully have some upside to that in this new range of 17% to 21% EBITDA margins into 2022. Remember these are goals, so there's short of guidance meaning the models are all influx and we might have targets out there, want people to understand we're working to be a growth oriented company, improve our profitability profile and establish what looks to be now a slightly higher EBITDA margins as well. So we'll state those as goals not guidance for 2022, but we thought we would give some context as we look forward. It's not only the contributions of our long-standing product portfolio that give us confidence, but it's the market's enthusiastic response to our newer solutions that it give us the confidence to put forward those kind of objectives and goals for 2022 and the market embrace our resuscitation solution from the American Red Cross and many of our other exciting innovative products that are contributing to our growth with their unique outcomes driven approach, so I want to talk a bit about one of those, talk pretty extensively and we'll more about the American Red Cross resuscitation suite, but today I want to spend a minute on Jane. So Jane is one of these new products, first of its kind in the market. Jane is an AI-driven clinical development solution that uses natural language processing powered by IBM Watson and that's a mouthful, but basically it is a cutting solution to helping assess the competency profile of staff and give them individualized intelligent plan of how to improve not only their knowledge of their work, but their critical thinking ability. So Jane is this truly is our kind of breakthrough expert system, it's kind of like a digital coach, particularly focused on our nursing population and Jane has been recognized industrywide with six prestigious awards from Brandon Hall in the last year and a unique approach through its newly awarded patent. So we couldn’t be more excited about the position of our Jane application set and so a bit of business progress as well. In 2021 we first began offering Jane at scale, our goal was to average one sale of Jane per week and as reported last quarter, we did achieve that throughout 2020. So I believe it's about 52 sales of Jane that were in the books last year, but this year we continue this good momentum in the second quarter for example have 23 new sales of more than one a week during the second quarter alone. So it's good to see that new product gaining some traction in the market. And as customer utilization grows and Jane's capabilities to expand, we report updating you on how Jane is changing the industry. It's a really exciting product and it's more than just a singular product. It's kind of a framework that we can attach more and more capabilities to it so work were excited about Jane. An important part of our strategic and patent focus now and in the last several years has involved these key transitions. We've articulated these three transitions. We use the word transition kind of in a way to infer risk that we were transitioning our business to achieve higher margins and we articulated a story of three transitions over the last three years and each of them had some I guess I'll characterize as major business risk and the great thing about today is I believe we crossed an inflection point where the major business risks what kind of point the substantial [ph] rest of the threat to our business is gone and we're really in the state now, we're trying to assess what's the opportunity behind these transitions. In other words, I think we're through some of the questions for example when we launched the Red Cross Resuscitation Suite program, would it be acceptable? We're beyond the acceptance now. We're in all 50 states hundreds and hundreds of contracts, system adoption and so it is beyond the ex-essential pair of launching new product and it fails in the market. Now the question is how good can it be and it's a better place to be right now. In addition the product adoption of VerityStream. So we built the new platform, the VerityStream platform called CredentialStream Application Set and we launched it. We were excited about it, but you never know how that's going to go and now again with over 400 contracts on VerityStream, the new CredentialStream platform, I think the acceptance of the market or the market adoption and acceptance of as a cutting edge platform we're kind of beyond questioning that. Now it's just a matter of how much market share can we get and our teams are really excited that they seem to be winning really well in the market with the new CredentialStream SaaS-based application. And then finally this third transition, I am trying to retire the word transitioning and just give you operational updates from here forward, but the third transition was about the HealthStream platform and while it's still an im-mature platform it is starting to be the interconnection tissue between all of our application sets and we've proven that some of the core functionality of the platform works for example the Red Cross Resuscitation Suite program takes advantage of the pass architecture to use the identity management and log infrastructure in the past architecture. So we know it works and we're excited to past this point of talking about the transitional risk and just start to provide more normalized operational updates on these three business initiatives now that I'll call them. So a little more detail on each of those but I've covered some already, but on the Red Cross Resuscitation Suite we thought we would share a few milestones on it. As I mentioned we're in all 50 states now. So again product adoption not a question anymore and in fact we've masked well over 0.5 million subscriptions at this point for the new product which is really quite staggering that we've been able to move that much market share to the American Red Cross Resuscitation Suite program really in a very short time since its launch in February of '19. So we continue to be excited about the product and in fact as we think about it, what's really great too is that the portfolio around resuscitation has also expanded and so in February of 2020, we now sell additional product called the Stable program and it's a leading neonatal education program around stabilizing neonates and resuscitation as a component of it and this highly expected program is now available online exclusively through HealthStream and we had strong sales in the second quarter adding to our thousands of subscriptions for the Stable program and again, this is in the portfolio of resuscitation. So not only have we found success with the American Red Cross Resuscitation Suite program, but the complimentary products that can be built around, surround and supportive of that program are beginning to gain traction in the market and so organizations like Akron Children's hospital or Spirits Healthcare [ph] and Ascension Health are adopting the stable program, which is really fantastic to see. So I'm pleased to see diversification of that portfolio area of our company as well as success as the core product, which again American Red Cross. So I've talked a bit already about the operational update on VerityStream, but I thought a little more color would be useful. During the second quarter of 2021 in fact, 42 new customer accounts contracted for the VerityStream application suite, which is called Credential Stream and that brings our cumulative total to well over 400 accounts. These accounts represent a mix of new customers and existing customers who are choosing to migrate from our legacy credentialing and privileging platforms for the new VerityStream application suite. And so some of these customers that we contract in the second quarter are name brands that people may represent a high quality health systems like Sentara Health, Shan [ph] Healthcare at the University of Florida and even Mercy Health System has selected Credential Stream application set. And importantly just it's good to know that all of our new customers, including the ones I just mentioned are coming on to the enterprise solution, the Credential Stream enterprise solution. So it's our top solution and the one that we built as a result of studying and building from the acquisitions we've made over the last say eight years. So we're excited to be gaining traction with that application set. And then finally the Health Stream platform is getting exciting. Now we think of it as connective tissue, almost like an operating system that can help us improve data mobility between applications that HealthStream offers, help us improve portability of data about the people in our ecosystem and so it is exciting to see that we added 180,000 net new Health Stream subscriptions by embedding some access to those technologies into the contracts that we're signing -- the new contractor we're signing. So that brings our cumulative total to 4.52 million subscriptions through the Health Stream technologies capabilities and solutions, which we're really, really excited about. At this time, I'd like to turn it over to Scotty Roberts for more detailed look at our financials and then we'll swing back around at the end and talk about the investments we want to make and some of the strategy and philosophy around our relatively new, we call it the third leg of our stool, but our relatively new scheduling capacity management business. So Scottie I'll turn it over to you.